Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children8610.24287/1726-1708-2015-14-1-16-25ОСТРЫЙ ЛИМФОБЛАСТНЫЙ ЛЕЙКОЗComparative analysis of dexamethasone and methylprednisolone efficacy in induction therapy of childhood acute lymphoblastic leukemia: Results of ALL-MB 2002 multicenter studyСравнительный анализ эффективности дексаметазона и метилпреднизолона в индукции ремиссии острого лимфобластного лейкоза у детей: результаты мультицентрового исследования ALL-MB 2002YudinaN. B.ЮдинаНаталья Борисовна
Russian Federation
uri@comch.ruKarachunskyA. I.КарачунскийАлександр Исаакович
Russian Federation
aikarat@mail.ruRumyantsevaYu. V.РумянцеваЮлия Васильевна
Russian Federation
j.roumiantseva@mail.ruLagoikoS. N.ЛагойкоСветлана Николаевна
Russian Federation
lagoiko80@mail.ruTallenGescheTallenG. .
Russian Federation
gesche.tallen@charite.deAleinikovaO. V.АлейниковаОльга Витальевна
Russian Federation
Aleinikova2004@mail.ruBydanovO. I.БыдановОлег Иванович
Russian Federation
budanov@oncology.byKorepanovaN. V.КорепановаНаталья Владимировна
Russian Federation
korepanova.natalia@gmail.comMansurovaE. G.МансуроваЕкатерина Геннадьевна
Russian Federation
mansurova2003@mail.ruBaidunL. V.БайдунЛюдмила Васильевна
Russian Federation
baidunlv@gmail.comNasedkinaT. V.НаседкинаТатьяна Васильевна
Russian Federation
korepanova.natalia@gmail.comVon StackelbergA. .
Russian Federation
arend.stackelberg@charite.deNovichkovaG. A.НовичковаГалина Анатольевна
Russian Federation
Galina.Novichkova@fccho-moscow.ruMaschanA. A.МасчанАлексей Александрович
Russian Federation
amaschan@mail.ruLitvinovD. V.ЛитвиновДмитрий Витальевич
Russian Federation
litvinov_d_v@mail.ruMyakovaN. V.МяковаНаталья Валерьевна
Russian Federation
nmiakova@mail.ruPonomarevaN. I.ПономареваНаталья Игоревна
Russian Federation
iga007@post.ruKondratchikK. L.КондратчикКонстантин Леонидович
Russian Federation
Morozov-14@yandex.ruFechinaL. G.ФечинаЛариса Геннадьевна
Russian Federation
childrens_oncology@mail.ruStrenevaO. V.СтреневаОльга Владимировна
Russian Federation
strenevaov@odkb.ruSharapovaG. R.ШараповаГюзель Рафаиловна
Russian Federation
sharapova.okdb@mail.ruShamardinaA. V.ШамардинаАнастасия Вячеславовна
Russian Federation
shav@gem.nnov.ruGerbekI. E.ГербекИнна Эмильевна
Russian Federation
Gerinna70@mail.ruShapochnikA. P.ШапочникАлександр Петрович
Russian Federation
shapochnik@mail.ruRumyantsevA. G.РумянцевАлександр Григорьевич
Russian Federation
Alexander.Rumyantsev@fccho-moscow.ruHenzeG. .
Russian Federation
guenter.henze@charite.deVoronezh Regional Pediatric Clinical Hospital No 1Воронежская областная детская клиническая больница № 1Federal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry RogachevФедеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава РоссииRussian National Research Medical University named after N.I.PirogovРоссийский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава РоссииCharité-Universitätsmedizin BerlinRepublican Center of Pediatric Oncology, Hematology, and ImmunologyРеспубликанский научно-практический центр детской онкологии, гематологии и иммунологии Минздрава Республики БеларусьRussian Pediatric Clinical HospitalРоссийская детская клиническая больница Минздрава РоссииMorozovskaya Pediatric Municipal Clinical HospitalМорозовская детская городская клиническая больница Департамента здравоохранения МосквыRegional Pediatric Clinical Hospital No 1Областная детская клиническая больница № 1Nizhnevartovsk Regional Pediatric Clinical HospitalНижневартовская окружная клиническая детская больницаNizhny Novgorod Regional Pediatric Clinical HospitalНижегородская областная детская клиническая больницаTomsk Regional Clinical HospitalТомская областная клиническая больницаOrenburg Regional Clinical Oncological CenterОренбургский областной клинический онкологический диспансер19022015141162519092018Copyright ©; 2015, «D. Rogachev NMRCPHOI»Copyright ©; 2015, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2015«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/86

This paper presents the results of randomized study of the efficacy of two glucocorticosteroids (GCS) in induction therapy of children and adolescents with acute lymphoblastic leukemia (ALL). A total of 1064 primary patients with ALL, aged 1-18 years, were registered from 18.04.2002 to 15.11.2006 in Russia and Belarus Republic. Randomization was carried out before induction therapy. The patients received the dexamethasone (Dexa; 6 mg/m2) “sleeve” of ALL-MB 2002 protocol (n = 539) or the methylprednisolone (MePred; 60 mg/m2) “sleeve” of the protocol (n = 525). The survival rates virtually did not differ: 10-year event-free survival (EFS) was 73 ± 2% in the Dexa group vs. 70 ± 2% in MePred group, p = 0.260; 10-year overall survival (OS) was 79 ± 2 and 77 ± 2%, respectively; p = 0.232; the incidence of relapses after ALL induction therapy by different GCS virtually did not differ. The incidence of isolated central nervous system relapses (1.7% in patients receiving Dexa and 3% in patients treated by MePred; p = 0.138) and of combined relapses with central nervous system involvement differed just negligibly (3.2% in Dexa group and 3.4% in MePred group; p = 0.937). The induction mortality was also similar (3.2% in Dexa group and 3.8% in MePred group; p = 0.677). Retrospective comparison in different age groups showed predominant efficacy of Dexa in children under 14 years of age. This fact deserves further research in prospective randomized multicenter studies.

детиострый лимфобластный лейкозглюкокортикостероидыдексаметазонметилпреднизолонтерапияиндукциятоксичностьchildrenacute lymphoblastic leukemiaglucocorticosteroidsdexamethasonemethylprednisolonetherapyinduction therapytoxicityKarachunskiy A., Herold R., von Stackelberg A., Miakova N., Timakow A., Mahortih T. et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia. 2008; 22(6): 1144-53.Jones B., Freeman A.I., Shuster J.J., Jacquillat C., Weil M., Pochedly C. et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol. 1991; 19(4): 269-75.Balis F.M., Lester C.M., Chrousos G.P., Heideman R.L., Poplack D.G. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987; 5(2): 202-7.Bostrom B.C., Sensel M.R., Sather H.N., Gaynon P.S., La M.K., Johnston K. et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003; 101(10): 3809-17.Stary J., Zimmermann M., Campbell M., Castillo L., Dibar E., Donska S. et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2014; 32(3): 174-84.Teuffel O., Kuster S.P., Hunger S.P., Conter V., Hitzler J., Ethier M.C. et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia. 2011; 25(8): 1232-8.Inaba H., Pui C.H. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010; 11(11): 1096-106.Igarashi S., Manabe A., Ohara A., Kumagai M., Saito T., Okimoto Y. et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol. 2005; 23(27): 6489-98.McNeer J.L., Nachman J.B. The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. Br J Haematol. 2010; 149(5): 638-52.Ito C., Evans W.E., McNinch L., Coustan-Smith E., Mahmoud H., Pui C.H. et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol. 1996; 14(8): 2370-6.Kaspers G.J., Veerman A.J., Popp-Snijders C., Lomecky M., Van Zantwijk C.H., Swinkels L.M. et al. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1996; 27(2): 114-21.Ryalls M.R., Pinkerton C.R., Meller S.T., Talbot D., McElwain T.J. High-dose methylprednisolone sodium succinate as a single agent in relapsed childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1992; 20(2): 119-23.Yetgin S., Gürgey A., Tuncer A.M., Cetin M., Ozbek N., Sayli T. et al. A comparison of the effect of high-dose methylprednisolone with conventional-dose prednisolone in acute lymphoblastic leukemia patients with randomization. Leuk Res. 1998; 22(6): 485-93.Bene M.C., Castoldi G., Knapp W., Ludwig W.D., Matutes E., Orfao A. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995; 9(10): 1783-6.Румянцева Ю.В., Карачунский А.И., Алейникова О.В., Фечина Л.Г., Шамардина А.В., Литвинов Д.В. и др. Эффективность протокола ALL-МВ-2002 у детей с острым лимфобластным лейкозом. Терапевтический архив. 2010; 82(7): 11-19.Machin D., Gardner M.J. Calculating confidence intervals for survival time analyses. Br Med J (Clin Res Ed). 1988; 296(6633): 1369-71.Piaggio G., Elbourne D.R., Pocock S.J., Evans S.J., Altman D.G.; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012; 308(24): 2594-604.Foody G.M. Classification accuracy comparison: hypothesis tests and the use of confidence intervals in evaluations of difference, equivalence and non-inferiority. Remote Sens Environ. 2009; 113(8): 1658-63.Song J.X. Sample size for simultaneous testing of rate differences in non-inferiority trials with multiple endpoints. Comput Stat Data Anal. 2009; 53(4): 1201-7.Labar B., Suciu S., Willemze R., Muus P., Marie J.P., Fillet G. et al. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica. 2010; 95(9): 1489-95.Toft N., Birgens H., Abrahamsson J., Bernell P., Griškevičius L, Hallböök H, et al. Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. Eur J Haematol. 2013; 90(5): 404-12.Bertrand Y., Suciu S., Benoit Y., Robert A., Nelken B., Uyttebroeck A. et al. Dexamethasone (DEX) (6mg/sm/d) and prednisolone (PRED) (60mg/sm/d) in induction therapy of childhood ALL are equally effective: results of the 2nd interim analysis of EORTC trial 58951. Blood (50th ASH Annual Meeting Abstracts. 6-9 December, San Francisco). 2008; 112(11): A-8.Mattano L.A. Jr., Sather H.N., Trigg M.E., Nachman J.B. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol. 2000; 18(18): 3262-72.Schrappe M., Zimmermann M., Moricke A., Mann G., Valsecchi M.G., Bartram C.R. et al. Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomized trial in 3655 patients (trial AIEOP-BFM ALL 2000). Blood (50th ASH Annual Meeting Abstracts. 6-9 December, San Francisco). 2008; 112(11): A-7.Schwartz C.L., Thompson E.B., Gelber R.D., Young M.L., Chilton D., Cohen H.J. et al. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol. 2001; 19(4): 1040-6.Hurwitz C.A., Silverman L.B., Schorin M.A., Clavell L.A., Dalton V.K., Glick K.M. et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000; 88(8): 1964-9.Diederich S., Eigendorff E., Burkhardt P., Quinkler M., Bumke-Vogt C., Rochel M. et al. 11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab. 2002; 87(12): 5695-701.Sai S., Nakagawa Y., Sakaguchi K., Okada S., Takahashi H., Hongo T. et al. Differential regulation of 11 beta-hydroxysteroid dehydrogenase-1 by dexamethasone in glucocorticoid-sensitive and -resistant childhood lymphoblastic leukemia. Leuk Res. 2009; 33(12): 1696-8.Tao Y., Shi J.M., Zhang Y.X., Gao L., Zhan F.H. Expression of 11 ß-hydroxysteroid dehydrogenase type 2 in lymphoblastic cells and its relationship with glucocorticoid sensitivity. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011; 19(1): 109-13.